The financials
NeoGenomics, Inc. by the numbers
NeoGenomics, Inc. (NEO) reported revenue of $202M in Q2 2026 (quarter ended June 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $2.2M (1.1% of revenue). For the full year FY2025, revenue was $727M (+10% year on year) and net income −$108M. Its largest product in 2026-Q1 was Client Direct Billing at $132M, 70% of the disclosed total, just ahead of Commercial Insurance at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $202M | $181M | +11% |
| Gross profit | $92M | $77M | +19% |
| Operating income | −$9.8M | −$48M | n/a |
| Net income | $2.2M | −$45M | to a profit |
| Diluted EPS | $0.02 | −$0.35 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Client Direct Billing | $132M | 70% |
| Commercial Insurance | $31M | 17% |
| Medicare And Other Governmental | $24M | 13% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $186.7M (-0.60%)
Commercial Insurance grew +24% year on yearSelf Pay Services -144% year on year
Segment Latestquarter on quarteryear on year
- Client Direct Billing$131.6M$131.6MQoQ -0.52%year on year +7.8%-0.52%+7.8%
- Commercial Insurance$30.9M$30.9MQoQ -4.7%year on year +24%-4.7%+24%
- Medicare And Other Governmental$24.1M$24.1MQoQ +5.1%year on year +14%+5.1%+14%
- Self Pay Services−$17.0K−$17.0KQoQ -125%year on year -144%-125%-144%
Diagnostics & Research
Ranks #7 of 29 by Smart Score